Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations

This publication has 9 references indexed in Scilit:

• Eucast Technical Note on daptomycin
  Clinical Microbiology and Infection, 2006
• Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections
  Expert Opinion on Investigational Drugs, 2004
• Daptomycin: Another Novel Agent for Treating Infections Due to Drug‐Resistant Gram‐Positive Pathogens
  Clinical Infectious Diseases, 2004
• Clinical Relevance of Bacteriostatic versus Bactericidal Mechanisms of Action in the Treatment of Gram‐Positive Bacterial Infections
  Clinical Infectious Diseases, 2004
• Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects
  Antimicrobial Agents and Chemotherapy, 2003
• Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial
  Clinical Pharmacokinetics, 2003
• In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains
  Antimicrobial Agents and Chemotherapy, 2000
• Penetration of vancomycin into human lung tissue
  Journal of Antimicrobial Chemotherapy, 1996
• Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration
  Journal of Hospital Infection, 1986